Current Protein & Peptide ScienceCurrent Protein & Peptide ScienceCurrent Protein & Peptide Science1389-20371875-5550Bentham Science64542510.2174/0113892037307940240606075208Life SciencesResearch ArticleExploring the Potential Role of Phytopharmaceuticals in Alleviating Toxicities of Chemotherapeutic AgentsKatolkarUjwalinfo@benthamscience.netSuranaSanjayinfo@benthamscience.netDepartment of Pharmacology,, R.C. Patel Institute of Pharmaceutical Education and ResearchDepartment of Pharmacology, R.C. Patel Institute of Pharmaceutical Education and Research01102024251075377911012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1389-2037/article/view/645425

Background:Chemotherapy is the mainstay of cancer treatment, bringing patients optimism about recurrence and survival. However, the clinical effectiveness of chemotherapeutic drugs is frequently jeopardized by their intrinsic toxicity, resulting in side effects affecting the quality of life of cancer patients. This analysis explores the ethnopharmacological impact of phytopharmaceuticals, highlighting their traditional use in many cultures. The present study, which takes its cues from indigenous knowledge, aims to close the knowledge gap between traditional medicine and modern medicine in reducing the toxicities of chemotherapy treatments.

Aim:The present in-depth study aims to highlight the current research and upcoming developments in phytopharmaceuticals for reducing the toxicity of chemotherapeutic drugs. Further, we address the mechanisms through which phytopharmaceuticals may reduce chemotherapy-induced side effects that include nausea, vomiting, myelosuppression, nephropathy, neuropathy, and cardiotoxicity using data from a variety of preclinical and clinical investigations.

Materials and Methods:The literature search was carried out by employing search engines such as PubMed and Google Scholar with keywords such as cancer, chemotherapy, CNS toxicity, hematopoietic toxicity, renal toxicity, GI toxicity, CNS toxicity, and phytopharmaceuticals.

Results:Bioactive chemicals found in plants, such as fruits, vegetables, herbs, and spices, are being studied for their capacity to improve the safety and acceptability of chemotherapy regimens. The current review also dives into the investigation of phytopharmaceuticals as adjuvant medicines in cancer treatment, which is a viable path for addressing the pressing need to lessen chemotherapy-induced toxicities.

Conclusion:The present review revealed that the potential of phytopharmaceuticals in alleviating chemotherapeutic drug toxicities would pave the way for better cancer treatment and patient outcomes, harmonizing with the larger trend towards personalized and holistic approaches to chemotherapy.

Cancerchemotherapychemotherapy-induced toxicitiesphytopharmaceuticalsproto-oncogenesoncogenes.Mathur, G.; Nain, S.; Sharma, P.K. Cancer: An overview. Acad. J. Cancer Res., 2015, 8(1), 01-9.Brennan, K; Offiah, G; McSherry, EA; Hopkins, AM Tight junctions: A barrier to the initiation and progression of breast cancer? J. Biomed. Biotechnol., 2010, 2010, 460607.Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol., 2007, 302(1), 1-12. doi: 10.1016/j.ydbio.2006.08.028 PMID: 16989803Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell., 2000, 100(1), 57-70.Kreeger, P.K.; Lauffenburger, D.A. Cancer systems biology: A network modeling perspective. Carcinogenesis, 2010, 31(1), 2-8. doi: 10.1093/carcin/bgp261 PMID: 19861649Fu, B.; Wang, N.; Tan, H.Y.; Li, S.; Cheung, F.; Feng, Y. Multi-component herbal products in the prevention and treatment of chemotherapy-associated toxicity and side effects: A review on experimental and clinical evidences. Front. Pharmacol., 2018, 9, 1394. doi: 10.3389/fphar.2018.01394 PMID: 30555327Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 2005, 4(3), 206-220. doi: 10.1038/nrd1657 PMID: 15729362Ko, J.K.; Auyeung, K.K. Target-oriented mechanisms of novel herbal therapeutics in the chemotherapy of gastrointestinal cancer and inflammation. Curr. Pharm. Des., 2013, 19(1), 48-66. PMID: 22950499Abbas, Z.; Rehman, S. An overview of cancer treatment modalities. Neoplasm., 2018, 1, 139-157.Sharma, V; Gupta, A; Sharma, A; Bisht, S; Scholar, UG Extraction of brain tumour using graphical user interface in MATLAB. IJCRT, 2020, 8(6), 1-8.Menon, S; Thomas, B Use of multi omics data in precision medicine and cancer research with applications in tumor subtyping, prognosis, and diagnosis. Int. J. Adv. Nurs. Edu. Res., 2021, 6(5), 19-29.Ghoshal, S.; Rigney, G.; Cheng, D.; Brumit, R.; Gee, M.S.; Hodin, R.A.; Lillemoe, K.D.; Levine, W.C.; Succi, M.D. Institutional surgical response and associated volume trends throughout the COVID-19 pandemic and postvaccination recovery period. JAMA Netw. Open, 2022, 5(8), e2227443-e2227443. doi: 10.1001/jamanetworkopen.2022.27443 PMID: 35980636Yabroff, K.R.; Wu, X.C.; Negoita, S.; Stevens, J.; Coyle, L.; Zhao, J.; Mumphrey, B.J.; Jemal, A.; Ward, K.C. Association of the COVID-19 pandemic with patterns of statewide cancer services. J. Natl. Cancer Inst., 2022, 114(6), 907-909. doi: 10.1093/jnci/djab122 PMID: 34181001Chen, R.; Aschmann, H.E.; Chen, Y.H.; Glymour, M.M.; Bibbins-Domingo, K.; Stokes, A.C.; Kiang, M.V. Racial and ethnic disparities in estimated excess mortality from external causes in the US, March to December 2020. JAMA Intern. Med., 2022, 182(7), 776-778. doi: 10.1001/jamainternmed.2022.1461 PMID: 35532918Woolf, S.H.; Chapman, D.A.; Sabo, R.T.; Zimmerman, E.B. Excess deaths from COVID-19 and other causes in the US, March 1, 2020, to January 2, 2021. JAMA, 2021, 325(17), 1786-1789. doi: 10.1001/jama.2021.5199 PMID: 33797550Gaidai, O.; Yan, P.; Xing, Y. Future world cancer death rate prediction. Sci. Rep., 2023, 13(1), 303. doi: 10.1038/s41598-023-27547-x PMID: 36609490Ostrom, Q.; Kruchko, C.; Neff, C.; Firth, A.; Sherman, R. The central brain tumor registry of the united states histopathological grouping scheme provides clinically relevant brain and other central nervous system categories for cancer registry data. J. Registry Manag., 2022, 49(4), 139-152. PMID: 37260822NAACCR. Cancer in North America: 2015-2019. Volume Two: Registry-Specific Cancer Incidence in the United States and Canada North American Association of Central Cancer Registries. Inc. 2022. Available From: https://www.naaccr.org/wp-content/uploads/2022/06/CiNA.2015-2019.v2.incidence.pdfLiu, B.; Zhu, L.; Zou, J.; Chen, H.S.; Miller, K.D.; Jemal, A.; Siegel, R.L.; Feuer, E.J. Updated methodology for projecting US-and state-level cancer counts for the current calendar year: Part I: Spatio-temporal modeling for cancer incidence. Cancer Epidemiol. Biomarkers Prev., 2021, 30(9), 1620-1626. doi: 10.1158/1055-9965.EPI-20-1727 PMID: 34162657Miller, K.D.; Siegel, R.L.; Liu, B.; Zhu, L.; Zou, J.; Jemal, A.; Feuer, E.J.; Chen, H.S. Updated methodology for projecting US-and state-level cancer counts for the current calendar year: Part II: Evaluation of incidence and mortality projection methods. Cancer Epidemiol. Biomarkers Prev., 2021, 30(11), 1993-2000. doi: 10.1158/1055-9965.EPI-20-1780 PMID: 34404684Pickle, L.W.; Hao, Y.; Jemal, A.; Zou, Z.; Tiwari, R.C.; Ward, E.; Hachey, M.; Howe, H.L.; Feuer, E.J. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J. Clin., 2007, 57(1), 30-42. doi: 10.3322/canjclin.57.1.30 PMID: 17237034Garraway, L.A.; Lander, E.S. Lessons from the cancer genome. Cell, 2013, 153(1), 17-37. doi: 10.1016/j.cell.2013.03.002 PMID: 23540688Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.J.R.; Behjati, S.; Biankin, A.V.; Bignell, G.R.; Bolli, N.; Borg, A.; Børresen-Dale, A.L.; Boyault, S.; Burkhardt, B.; Butler, A.P.; Caldas, C.; Davies, H.R.; Desmedt, C.; Eils, R.; Eyfjörd, J.E.; Foekens, J.A.; Greaves, M.; Hosoda, F.; Hutter, B.; Ilicic, T.; Imbeaud, S.; Imielinski, M.; Jäger, N.; Jones, D.T.W.; Jones, D.; Knappskog, S.; Kool, M.; Lakhani, S.R.; López-Otín, C.; Martin, S.; Munshi, N.C.; Nakamura, H.; Northcott, P.A.; Pajic, M.; Papaemmanuil, E.; Paradiso, A.; Pearson, J.V.; Puente, X.S.; Raine, K.; Ramakrishna, M.; Richardson, A.L.; Richter, J.; Rosenstiel, P.; Schlesner, M.; Schumacher, T.N.; Span, P.N.; Teague, J.W.; Totoki, Y.; Tutt, A.N.J.; Valdés-Mas, R.; van Buuren, M.M.; van ’t Veer, L.; Vincent-Salomon, A.; Waddell, N.; Yates, L.R.; Zucman-Rossi, J.; Andrew Futreal, P.; McDermott, U.; Lichter, P.; Meyerson, M.; Grimmond, S.M.; Siebert, R.; Campo, E.; Shibata, T.; Pfister, S.M.; Campbell, P.J.; Stratton, M.R. Signatures of mutational processes in human cancer. Nature, 2013, 500(7463), 415-421. doi: 10.1038/nature12477 PMID: 23945592Negrini, S.; Gorgoulis, V.G.; Halazonetis, T.D. Genomic instability — an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol., 2010, 11(3), 220-228. doi: 10.1038/nrm2858 PMID: 20177397Vogelstein, B; Papadopoulos, N; Velculescu, VE; Zhou, S; Diaz, LA, Jr; Kinzler, KW Cancer genome landscapes. Science, 2013, 339(6127), 1546-58. doi: 10.1126/science.1235122Timp, W.; Feinberg, A.P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer, 2013, 13(7), 497-510. doi: 10.1038/nrc3486 PMID: 23760024You, J.S.; Jones, P.A. Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell, 2012, 22(1), 9-20. doi: 10.1016/j.ccr.2012.06.008 PMID: 22789535Xie, X.; Lu, J.; Kulbokas, E.J.; Golub, T.R.; Mootha, V.; Lindblad-Toh, K.; Lander, E.S.; Kellis, M. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature, 2005, 434(7031), 338-345. doi: 10.1038/nature03441 PMID: 15735639Calin, G.A.; Liu, C.G.; Sevignani, C.; Ferracin, M.; Felli, N.; Dumitru, C.D.; Shimizu, M.; Cimmino, A.; Zupo, S.; Dono, M.; Dell’Aquila, M.L.; Alder, H.; Rassenti, L.; Kipps, T.J.; Bullrich, F.; Negrini, M.; Croce, C.M. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA, 2004, 101(32), 11755-11760. doi: 10.1073/pnas.0404432101 PMID: 15284443Croce, C.M.; Croce, M.D. Oncogenes and Cancer. N. Engl. J. Med., 2008, 358(5), 502-511. doi: 10.1056/NEJMra072367 PMID: 18234754Murakami, Y.; Tateyama, S.; Rungsipipat, A.; Uchida, K.; Yamaguchi, R. Amplification of the cyclin A gene in canine and feline mammary tumors. J. Vet. Med. Sci., 2000, 62(7), 783-787. doi: 10.1292/jvms.62.783 PMID: 10945302Murakami, Y.; Tateyama, S.; Rungsipipat, A.; Uchida, K.; Yamaguchi, R. Immunohistochemical analysis of cyclin A, cyclin D1 and P53 in mammary tumors, squamous cell carcinomas and basal cell tumors of dogs and cats. J. Vet. Med. Sci., 2000, 62(7), 743-750. doi: 10.1292/jvms.62.743 PMID: 10945293Sherbenou, D.W.; Druker, B.J. Applying the discovery of the Philadelphia chromosome. J. Clin. Invest., 2007, 117(8), 2067-2074. doi: 10.1172/JCI31988 PMID: 17671641Figueiredo, J.F.; Culver, S.; Behling-Kelly, E.; Breen, M.; Friedrichs, K.R. Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog. Vet. Clin. Pathol., 2012, 41(3), 362-368. doi: 10.1111/j.1939-165X.2012.00450.x PMID: 22747755Breen, M.; Modiano, J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionship. Chromosome Res., 2008, 16(1), 145-154. doi: 10.1007/s10577-007-1212-4 PMID: 18293109Cruz Cardona, J.A.; Milner, R.; Alleman, A.R.; Williams, C.; Vernau, W.; Breen, M.; Tompkins, M. BCR-ABL translocation in a dog with chronic monocytic leukemia. Vet. Clin. Pathol., 2011, 40(1), 40-47. doi: 10.1111/j.1939-165X.2010.00277.x PMID: 21143615Culver, S.; Ito, D.; Borst, L.; Bell, J.S.; Modiano, J.F.; Breen, M. Molecular characterization of canine BCR-ABL–positive chronic myelomonocytic leukemia before and after chemotherapy. Vet. Clin. Pathol., 2013, 42(3), 314-322. doi: 10.1111/vcp.12055 PMID: 23800034Misdorp, W.; Meuten, D.J. Tumors in domestic animals; , 2002.Moulton, J.E. Tumors in domestic animals; Univ of California Press, 1978.Pietras, K.; Östman, A. Hallmarks of cancer: Interactions with the tumor stroma. Exp. Cell Res., 2010, 316(8), 1324-1331. doi: 10.1016/j.yexcr.2010.02.045 PMID: 20211171Boyle, J.O.; Hakim, J.; Koch, W.; van der Riet, P.; Hruban, R.H.; Roa, R.A.; Correo, R.; Eby, Y.J.; Ruppert, J.M.; Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 1993, 53(19), 4477-4480. PMID: 8402617Bieging, K.T.; Mello, S.S.; Attardi, L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer, 2014, 14(5), 359-370. doi: 10.1038/nrc3711 PMID: 24739573Burkhart, D.L.; Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer, 2008, 8(9), 671-682. doi: 10.1038/nrc2399 PMID: 18650841Olivier, M; Hollstein, M; Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol., 2010, 2(1), a001008.Diller, L.; Kassel, J.; Nelson, C.E.; Gryka, M.A.; Litwak, G.; Gebhardt, M.; Bressac, B.; Ozturk, M.; Baker, S.J.; Vogelstein, B. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 1990, 10(11), 5772-5781. PMID: 2233717Cullen, J.M.; Breen, M. An overview of molecular cancer pathogenesis, prognosis, and diagnosis; Tumors Domest Anim, 2016, pp. 1-26. doi: 10.1002/9781119181200.ch1Tian, H.; Faje, A.T.; Lee, S.L.; Jorgensen, T.J. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. Neoplasia, 2002, 4(2), 171-180. doi: 10.1038/sj.neo.7900219 PMID: 11896572Bernstein, C.; Bernstein, H.; Payne, C.M.; Garewal, H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat. Res. Rev. Mutat. Res., 2002, 511(2), 145-178. doi: 10.1016/S1383-5742(02)00009-1 PMID: 12052432Rayess, H.; Wang, M.B.; Srivatsan, E.S. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer, 2012, 130(8), 1715-1725. doi: 10.1002/ijc.27316 PMID: 22025288Alhmoud, J.F.; Woolley, J.F.; Al Moustafa, A.E.; Mallei, M.I. DNA damage/repair management in cancers. In: Adv. Med. Biochem. Genomics, Physiol. Pathol; , 2021; pp. 309-339.Wright, W.E.; Shay, J.W. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat. Med., 2000, 6(8), 849-851. doi: 10.1038/78592 PMID: 10932210Novak, K.D. Telomeres and telomerases in cancer. MedGenMed, 2003, 5(1), 21. PMID: 12827082Renwick, M.G.; Argyle, D.J.; Long, S.; Nixon, C.; Gault, E.A.; Nasir, L. Telomerase activity and telomerase reverse transcriptase catalytic subunit expression in canine lymphoma: Correlation with Ki67 immunoreactivity. Vet. Comp. Oncol., 2006, 4(3), 141-150. doi: 10.1111/j.1476-5829.2006.00103.x PMID: 19754811Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-364. doi: 10.1016/S0092-8674(00)80108-7 PMID: 8756718Debela, D.T.; Muzazu, S.G.Y.; Heraro, K.D.; Ndalama, M.T.; Mesele, B.W.; Haile, D.C.; Kitui, S.K.; Manyazewal, T. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med., 2021, 9, 20503121211034366. doi: 10.1177/20503121211034366 PMID: 34408877Goss, P.E.; Strasser-Weippl, K.; Lee-Bychkovsky, B.L.; Fan, L.; Li, J.; Chavarri-Guerra, Y.; Liedke, P.E.R.; Pramesh, C.S.; Badovinac-Crnjevic, T.; Sheikine, Y.; Chen, Z.; Qiao, Y.; Shao, Z.; Wu, Y.L.; Fan, D.; Chow, L.W.C.; Wang, J.; Zhang, Q.; Yu, S.; Shen, G.; He, J.; Purushotham, A.; Sullivan, R.; Badwe, R.; Banavali, S.D.; Nair, R.; Kumar, L.; Parikh, P.; Subramanian, S.; Chaturvedi, P.; Iyer, S.; Shastri, S.S.; Digumarti, R.; Soto-Perez-de-Celis, E.; Adilbay, D.; Semiglazov, V.; Orlov, S.; Kaidarova, D.; Tsimafeyeu, I.; Tatishchev, S.; Danishevskiy, K.D.; Hurlbert, M.; Vail, C.; St Louis, J.; Chan, A. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol., 2014, 15(5), 489-538. doi: 10.1016/S1470-2045(14)70029-4 PMID: 24731404Purushotham, A.D.; Lewison, G.; Sullivan, R. The state of research and development in global cancer surgery. Ann. Surg., 2012, 255(3), 427-432. doi: 10.1097/SLA.0b013e318246591f PMID: 22281701Vasen, H.; Watson, P.; Mecklin, J.; Lynch, H. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology, 1999, 116(6), 1453-1456. doi: 10.1016/S0016-5085(99)70510-X PMID: 10348829Ringborg, U.; Bergqvist, D.; Brorsson, B.; Cavallin-ståhl, E.; Ceberg, J.; Einhorn, N.; Frödin, J.; Järhult, J.; Lamnevik, G.; Lindholm, C.; Littbrand, B.; Norlund, A.; Nylén, U.; Rosén, M.; Svensson, H.; Möller, T.R. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions. Acta Oncol., 2003, 42(5-6), 357-365. doi: 10.1080/02841860310010826 PMID: 14596499Delaney, G.; Jacob, S.; Featherstone, C.; Barton, M. The role of radiotherapy in cancer treatment. Cancer, 2005, 104(6), 1129-1137. doi: 10.1002/cncr.21324 PMID: 16080176Begg, A.C.; Stewart, F.A.; Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer, 2011, 11(4), 239-253. doi: 10.1038/nrc3007 PMID: 21430696Barnett, G.C.; West, C.M.L.; Dunning, A.M.; Elliott, R.M.; Coles, C.E.; Pharoah, P.D.P.; Burnet, N.G. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. Nat. Rev. Cancer, 2009, 9(2), 134-142. doi: 10.1038/nrc2587 PMID: 19148183Bernier, J.; Hall, E.J.; Giaccia, A. Radiation oncology: A century of achievements. Nat. Rev. Cancer, 2004, 4(9), 737-747. doi: 10.1038/nrc1451 PMID: 15343280Nygren, P. What is cancer chemotherapy? Acta Oncol., 2001, 40(2-3), 166-174. doi: 10.1080/02841860151116204 PMID: 11441929Pratt, W.B. The anticancer drugs; Oxford University Press: USA, 1994.Johnson, S.W. Cisplatin and its analogues; Cancer Princ Pract Oncol, 2005.Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind. Ann. Oncol., 1994, 5(6), 495-505. doi: 10.1093/oxfordjournals.annonc.a058903 PMID: 7918121Dancey, J.; Eisenhauer, E.A. Current perspectives on camptothecins in cancer treatment. Br. J. Cancer, 1996, 74(3), 327-338. doi: 10.1038/bjc.1996.362 PMID: 8695345Gyanani, V. Turning stealth liposomes into cationic liposomes for anticancer drug delivery., 2013,Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2(10), 750-763. doi: 10.1038/nrc903 PMID: 12360278Yao, X.; Panichpisal, K.; Kurtzman, N.; Nugent, K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci., 2007, 334(2), 115-124. doi: 10.1097/MAJ.0b013e31812dfe1e PMID: 17700201Pfeffer, B.; Tziros, C.; Katz, R.J. Current concepts of anthracycline cardiotoxicity: Pathogenesis, diagnosis and prevention. Br. J. Cardiol., 2009, 16(2)Partridge, A.H.; Burstein, H.J.; Winer, E.P. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J. Natl. Cancer Inst. Monogr., 2001, 2001(30), 135-142. doi: 10.1093/oxfordjournals.jncimonographs.a003451 PMID: 11773307Fabbrocini, G.; Cameli, N.; Romano, M.C.; Mariano, M.; Panariello, L.; Bianca, D.; Monfrecola, G. Chemotherapy and skin reactions. J. Exp. Clin. Cancer Res., 2012, 31(1), 50. doi: 10.1186/1756-9966-31-50 PMID: 22640460de Vries Schultink, A.H.M.; Suleiman, A.A.; Schellens, J.H.M.; Beijnen, J.H.; Huitema, A.D.R. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur. J. Clin. Pharmacol., 2016, 72(6), 645-653. doi: 10.1007/s00228-016-2030-4 PMID: 26915815Vadhan-Raj, S. Management of chemotherapy-induced thrombocytopenia: Current status of thrombopoietic agents. Seminars in Hematology; Elsevier, 2009, pp. S26-S32. doi: 10.1053/j.seminhematol.2008.12.007Crawford, J.; Dale, D.C.; Lyman, G.H. Chemotherapy-induced neutropenia. Cancer, 2004, 100(2), 228-237. doi: 10.1002/cncr.11882 PMID: 14716755Lyman, G.H.; Poniewierski, M.S.; Culakova, E. Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. Expert Opin. Drug Saf., 2016, 15(4), 483-492. doi: 10.1517/14740338.2016.1146675 PMID: 26809103Feng, L.; Huang, Q.; Huang, Z.; Li, H.; Qi, X.; Wang, Y.; Liu, Z.; Liu, X.; Lu, L. Optimized animal model of cyclophosphamide-induced bone marrow suppression. Basic Clin. Pharmacol. Toxicol., 2016, 119(5), 428-435. doi: 10.1111/bcpt.12600 PMID: 27061017Ma, R.M.; Chen, C.Z.; Zhang, W.; You, J.; Huang, D.P.; Guo, G.L. Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer. Medicine (Baltimore), 2016, 95(13), e3240. doi: 10.1097/MD.0000000000003240 PMID: 27043697Barreto, J.N.; McCullough, K.B.; Ice, L.L.; Smith, J.A. Antineoplastic agents and the associated myelosuppressive effects: A review. J. Pharm. Pract., 2014, 27(5), 440-446. doi: 10.1177/0897190014546108 PMID: 25147158Kukec, R.R.; Grabnar, I.; Vovk, T.; Mrhar, A.; Kovac, V.; Cufer, T. Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiol. Oncol., 2015, 49(2), 173-180. doi: 10.2478/raon-2014-0050 PMID: 26029029Andersohn, F.; Konzen, C.; Garbe, E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med., 2007, 146(9), 657-665. doi: 10.7326/0003-4819-146-9-200705010-00009 PMID: 17470834Kaufman, D.W.; Kelly, J.P.; Issaragrisil, S.; Laporte, J.R.; Anderson, T.; Levy, M.; Shapiro, S.; Young, N.S. Relative incidence of agranulocytosis and aplastic anemia. Am. J. Hematol., 2006, 81(1), 65-67. doi: 10.1002/ajh.20489 PMID: 16369972Printz, M.A.; Dychter, S.S.; DeNoia, E.P.; Harrigan, R.; Sugarman, B.J.; Zepeda, M.; Souratha, J.; Kang, D.W.; Maneval, D.C. A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human hyaluronidase PH20 administered intravenously in healthy volunteers. Curr. Ther. Res. Clin. Exp., 2020, 93, 100604. doi: 10.1016/j.curtheres.2020.100604 PMID: 32963641Johnson, P.; Glennie, M. The mechanisms of action of rituximab in the elimination of tumor cells.Seminars in oncology; Elsevier, 2003, pp. 3-8. doi: 10.1053/sonc.2003.50025Motl, S.E.; Baskin, R.C. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: Case report and literature review. Pharmacotherapy, 2005, 25(8), 1151-1155. doi: 10.1592/phco.2005.25.8.1151 PMID: 16207108Nitta, E.; Izutsu, K.; Sato, T.; Ota, Y.; Takeuchi, K.; Kamijo, A.; Takahashi, K.; Oshima, K.; Kanda, Y.; Chiba, S.; Motokura, T.; Kurokawa, M. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann. Oncol., 2007, 18(2), 364-369. doi: 10.1093/annonc/mdl393 PMID: 17079695Hirayama, Y.; Kohda, K.; Konuma, Y.; Hirata, Y.; Kuroda, H.; Fujimi, Y.; Shirao, S.; Kobune, M.; Takimoto, R.; Matsunaga, T.; Kato, J. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab. Intern. Med., 2009, 48(1), 57-60. doi: 10.2169/internalmedicine.48.1368 PMID: 19122357National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available From: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfKuter, D.J. General aspects of thrombocytopenia, platelet transfusions, and thrombopoietic growth factors.Consultative hemostasis and thrombosis; Elsevier, 2019, pp. 108-126. doi: 10.1016/B978-0-323-46202-0.00007-8Schmied, L.; Höglund, P.; Meinke, S. Platelet-mediated protection of cancer cells from immune surveillance–possible implications for cancer immunotherapy. Front. Immunol., 2021, 12, 640578. doi: 10.3389/fimmu.2021.640578 PMID: 33777033Wright, J.H. A rapid method for the differential staining of blood films and malarial parasites. J. Med. Res., 1902, 7(1), 138-144. PMID: 19971449Potts, K.S.; Farley, A.; Dawson, C.A.; Rimes, J.; Biben, C.; de Graaf, C.; Potts, M.A.; Stonehouse, O.J.; Carmagnac, A.; Gangatirkar, P.; Josefsson, E.C.; Anttila, C.; Amann-Zalcenstein, D.; Naik, S.; Alexander, W.S.; Hilton, D.J.; Hawkins, E.D.; Taoudi, S. Membrane budding is a major mechanism of in vivo platelet biogenesis. J. Exp. Med., 2020, 217(9), e20191206. doi: 10.1084/jem.20191206 PMID: 32706855Balduini, C.L. 100-Year-Old Haematologica Images: The Quarrel About The Origin Of Platelets (II). Haematologica, 2020, 105(6), 1467. doi: 10.3324/haematol.2020.254011 PMID: 32482749Skverchinskaya, E.; Levdarovich, N.; Ivanov, A.; Mindukshev, I.; Bukatin, A. Anticancer drugs paclitaxel, carboplatin, doxorubicin, and cyclophosphamide alter the biophysical characteristics of red blood cells, in vitro. Biology (Basel), 2023, 12(2), 230. doi: 10.3390/biology12020230 PMID: 36829507Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4(4), 253-265. doi: 10.1038/nrc1317 PMID: 15057285Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584. doi: 10.1038/nrc2167 PMID: 17625587Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56(2), 185-229. doi: 10.1124/pr.56.2.6 PMID: 15169927Colombo, R.; Necco, A.; Vailati, G.; Milzani, A. Dose-dependence of doxorubicin effect on actin assembly in vitro. Exp. Mol. Pathol., 1988, 49(3), 297-304. doi: 10.1016/0014-4800(88)90002-0 PMID: 3197812Alves, A.C.; Ribeiro, D.; Nunes, C.; Reis, S. Biophysics in cancer: The relevance of drug-membrane interaction studies. Biochim. Biophys. Acta Biomembr., 2016, 1858(9), 2231-2244. doi: 10.1016/j.bbamem.2016.06.025 PMID: 27368477Shinohara, K.; Tanaka, K.R. The effects of adriamycin (doxorubicin HCl) on human red blood cells. Hemoglobin, 1980, 4(5-6), 735-745. doi: 10.3109/03630268008997741 PMID: 6254923Lyman, G.H.; Dale, D.C.; Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J. Clin. Oncol., 2003, 21(24), 4524-4531. doi: 10.1200/JCO.2003.05.002 PMID: 14673039Lyman, G.H.; Dale, D.C.; Friedberg, J.; Crawford, J.; Fisher, R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: A nationwide study. J. Clin. Oncol., 2004, 22(21), 4302-4311. doi: 10.1200/JCO.2004.03.213 PMID: 15381684Mauch, P.; Constine, L.; Greenberger, J.; Knospe, W.; Sullivan, J.; Liesveld, J.L.; Deeg, H.J. Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 1995, 31(5), 1319-1339. doi: 10.1016/0360-3016(94)00430-S PMID: 7713791Marsh, J.C. The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: A review. Cancer Res., 1976, 36(6), 1853-1882. PMID: 773531Bonfield, T.L.; Farver, C.F.; Barna, B.P.; Malur, A.; Abraham, S.; Raychaudhuri, B.; Kavuru, M.S.; Thomassen, M.J. Peroxisome proliferator-activated receptor-γ is deficient in alveolar macrophages from patients with alveolar proteinosis. Am. J. Respir. Cell Mol. Biol., 2003, 29(6), 677-682. doi: 10.1165/rcmb.2003-0148OC PMID: 12805087Schmiegelow, K.; Attarbaschi, A.; Barzilai, S.; Escherich, G.; Frandsen, T.L.; Halsey, C.; Hough, R.; Jeha, S.; Kato, M.; Liang, D.C.; Mikkelsen, T.S.; Möricke, A.; Niinimäki, R.; Piette, C.; Putti, M.C.; Raetz, E.; Silverman, L.B.; Skinner, R.; Tuckuviene, R.; van der Sluis, I.; Zapotocka, E. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus. Lancet Oncol., 2016, 17(6), e231-e239. doi: 10.1016/S1470-2045(16)30035-3 PMID: 27299279Braña, I.; Zamora, E.; Tabernero, J. Cardiotoxicity; Side Eff Med Cancer Ther Prev Treat, 2013, pp. 483-530.Cardinale, D.; Colombo, A.; Lamantia, G.; Colombo, N.; Civelli, M.; De Giacomi, G.; Rubino, M.; Veglia, F.; Fiorentini, C.; Cipolla, C.M. Anthracycline-Induced Cardiomyopathy. J. Am. Coll. Cardiol., 2010, 55(3), 213-220. doi: 10.1016/j.jacc.2009.03.095 PMID: 20117401Steinherz, L.J.; Steinherz, P.G.; Tan, C.T.C.; Heller, G.; Murphy, M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 1991, 266(12), 1672-1677. doi: 10.1001/jama.1991.03470120074036 PMID: 1886191Florescu, M.; Cinteza, M.; Vinereanu, D. Chemotherapy-induced Cardiotoxicity. Maedica (Buchar.), 2013, 8(1), 59-67. PMID: 24023601Khakoo, A.Y.; Liu, P.P.; Force, T.; Lopez-Berestein, G.; Jones, L.W.; Schneider, J.; Hill, J. Cardiotoxicity due to cancer therapy. Tex. Heart Inst. J., 2011, 38(3), 253-256. PMID: 21720463Jensen, B.V. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Seminars in oncology; Elsevier, 2006, pp. 15-21. doi: 10.1053/j.seminoncol.2006.04.022Jiji, R.S.; Kramer, C.M.; Salerno, M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J. Nucl. Cardiol., 2012, 19(2), 377-388. doi: 10.1007/s12350-012-9512-2 PMID: 22351492Seidman, A.; Hudis, C.; Pierri, M.K.; Shak, S.; Paton, V.; Ashby, M.; Murphy, M.; Stewart, S.J.; Keefe, D. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol., 2002, 20(5), 1215-1221. doi: 10.1200/JCO.2002.20.5.1215 PMID: 11870163Dolci, A.; Dominici, R.; Cardinale, D.; Sandri, M.T.; Panteghini, M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use. Am. J. Clin. Pathol., 2008, 130(5), 688-695. doi: 10.1309/AJCPB66LRIIVMQDR PMID: 18854260DeAngelis, L.M. Side effects of radiation therapy.Neurologic Complications of Cancer; DeAngelis, L.M.; Posner, J.B., Eds.; Oxford University Press: New York, 2009.Orlopp, K.; Schmidt-Wolf, I.G.H.; Urbach, H.; Schlegel, U. Acute central nervous symptoms in oncologic patients. Internist (Berl.), 2005, 46(1), 19-29. doi: 10.1007/s00108-004-1315-3 PMID: 15580462Ziske, C.G.; Schöttker, B.; Gorschlüter, M.; Mey, U.; Kleinschmidt, R.; Schlegel, U.; Sauerbruch, T.; Schmidt-Wolf, I.G.H. Acute transient encephalopathy after paclitaxel infusion: Report of three cases. Ann. Oncol., 2002, 13(4), 629-631. doi: 10.1093/annonc/mdf025 PMID: 12056715Verstappen, C.C.P.; Heimans, J.J.; Hoekman, K.; Postma, T.J. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 2003, 63(15), 1549-1563. doi: 10.2165/00003495-200363150-00003 PMID: 12887262Linnebank, M.; Pels, H.; Kleczar, N.; Farmand, S.; Fliessbach, K.; Urbach, H.; Orlopp, K.; Klockgether, T.; Schmidt-Wolf, I.G.H.; Schlegel, U. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology, 2005, 64(5), 912-913. doi: 10.1212/01.WNL.0000152840.26156.74 PMID: 15753437Linnebank, M.; Moskau, S.; Jürgens, A.; Simon, M.; Semmler, A.; Orlopp, K.; Glasmacher, A.; Bangard, C.; Vogt-Schaden, M.; Urbach, H.; Schmidt-Wolf, I.G.H.; Pels, H.; Schlegel, U. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro-oncol., 2009, 11(1), 2-8. doi: 10.1215/15228517-2008-082 PMID: 18806228Drachtman, R.A.; Cole, P.D.; Golden, C.B.; James, S.J.; Melnyk, S.; Aisner, J.; Kamen, B.A. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr. Hematol. Oncol., 2002, 19(5), 319-327. doi: 10.1080/08880010290057336 PMID: 12078863Becker, A.; Vezmar, S.; Linnebank, M.; Pels, H.; Bode, U.; Schlegel, U.; Jaehde, U. Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int. J. Clin. Pharmacol. Ther., 2007, 45(9), 504-515. doi: 10.5414/CPP45504 PMID: 17907593Perazella, M.A. Onco-Nephrology. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1713-1721. doi: 10.2215/CJN.02780312 PMID: 22879440Santos, M.L.C.; Brito, B.B.; Silva, F.A.F.; Botelho, A.C.S.; Melo, F.F. Nephrotoxicity in cancer treatment: An overview. World J. Clin. Oncol., 2020, 11(4), 190-204. doi: 10.5306/wjco.v11.i4.190 PMID: 32355641Małyszko, J.; Kozłowska, K.; Kozłowski, L.; Małyszko, J. Nephrotoxicity of anticancer treatment. Nephrol. Dial. Transplant., 2017, 32(6), 924-936. PMID: 28339935Perazella, M.A.; Shirali, A.C. Nephrotoxicity of cancer immunotherapies: Past, present and future. J. Am. Soc. Nephrol., 2018, 29(8), 2039-2052. doi: 10.1681/ASN.2018050488 PMID: 29959196Totzeck, M.; Schuler, M.; Stuschke, M.; Heusch, G.; Rassaf, T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int. J. Cardiol., 2019, 280, 163-175. doi: 10.1016/j.ijcard.2019.01.038 PMID: 30661849Stone, J.B.; DeAngelis, L.M. Cancer-treatment-induced neurotoxicity—focus on newer treatments. Nat. Rev. Clin. Oncol., 2016, 13(2), 92-105. doi: 10.1038/nrclinonc.2015.152 PMID: 26391778Perazella, M.A.; Izzedine, H. New drug toxicities in the onco-nephrology world. Kidney Int., 2015, 87(5), 909-917. doi: 10.1038/ki.2015.30 PMID: 25671763Choti, M.A. Chemotherapy-associated hepatotoxicity: Do we need to be concerned? Ann. Surg. Oncol., 2009, 16(9), 2391-2394. doi: 10.1245/s10434-009-0512-7 PMID: 19554374Jaeschke, H.; Gores, G.J.; Cederbaum, A.I.; Hinson, J.A.; Pessayre, D.; Lemasters, J.J. Mechanisms of Hepatotoxicity. Toxicol. Sci., 2002, 65(2), 166-176. doi: 10.1093/toxsci/65.2.166 PMID: 11812920Fontana, R.J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology, 2014, 146(4), 914-928.e1. doi: 10.1053/j.gastro.2013.12.032 PMID: 24389305Hoofnagle, J.H.; Björnsson, E.S. Drug-induced liver injury—types and phenotypes. N. Engl. J. Med., 2019, 381(3), 264-273. doi: 10.1056/NEJMra1816149 PMID: 31314970Björnsson, E. Hepatotoxicity by drugs: The most common implicated agents. Int. J. Mol. Sci., 2016, 17(2), 224. doi: 10.3390/ijms17020224 PMID: 26861310Mudd, T.W.; Guddati, A.K. Management of hepatotoxicity of chemotherapy and targeted agents. Am. J. Cancer Res., 2021, 11(7), 3461-3474. PMID: 34354855Floyd, J.; Mirza, I.; Sachs, B.; Perry, M.C. Hepatotoxicity of Chemotherapy. Semin. Oncol., 2006, 33(1), 50-67. doi: 10.1053/j.seminoncol.2005.11.002 PMID: 16473644Grigorian, A.; O’Brien, C.B. Hepatotoxicity secondary to chemotherapy. J. Clin. Transl. Hepatol., 2014, 2(2), 95-102. PMID: 26357620Periáñez-Párraga, L.; Martínez-López, I.; Ventayol-Bosch, P.; Puigventós-Latorre, F.; Delgado-Sánchez, O. Drug dosage recommendations in patients with chronic liver disease. Rev. Esp. Enferm. Dig., 2012, 104(4), 165-184. doi: 10.4321/S1130-01082012000400002 PMID: 22537365Choi, S.H. WHO traditional medicine strategy and activities. "Standardization with evidence-based approaches". J. Acupunct. Meridian Stud., 2008, 1(2), 153-154. doi: 10.1016/S2005-2901(09)60037-6 PMID: 20633469Cho, HJ; Yoon, IS Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein.es". Evid Based Complement. Alternat. Med., 2015, 2015, 736431. doi: 10.1155/2015/736431Oyebode, O.; Kandala, N.B.; Chilton, P.J.; Lilford, R.J. Use of traditional medicine in middle-income countries: A WHO-SAGE study. Health Policy Plan., 2016, 31(8), 984-991. doi: 10.1093/heapol/czw022 PMID: 27033366Asiimwe, J.B.; Nagendrappa, P.B.; Atukunda, E.C.; Kamatenesi, M.M.; Nambozi, G.; Tolo, C.U.; Ogwang, P.E.; Sarki, A.M. Prevalence of the use of herbal medicines among patients with cancer: A systematic review and meta-analysis. Evid. Based Complement. Alternat. Med., 2021, 2021, 1-18. doi: 10.1155/2021/9963038 PMID: 34055029McGrowder, D.A.; Miller, F.G.; Nwokocha, C.R.; Anderson, M.S.; Wilson-Clarke, C.; Vaz, K.; Anderson-Jackson, L.; Brown, J. Medicinal herbs used in traditional management of breast cancer: Mechanisms of action. Medicines (Basel), 2020, 7(8), 47. doi: 10.3390/medicines7080047 PMID: 32823812Damery, S.; Gratus, C.; Grieve, R.; Warmington, S.; Jones, J.; Routledge, P.; Greenfield, S.; Dowswell, G.; Sherriff, J.; Wilson, S. The use of herbal medicines by people with cancer: A cross-sectional survey. Br. J. Cancer, 2011, 104(6), 927-933. doi: 10.1038/bjc.2011.47 PMID: 21364591Molassiotis, A.; Yung, H.P.; Yam, B.M.; Chan, F.Y.; Mok, T. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: A randomised controlled trial. Support. Care Cancer, 2002, 10(3), 237-246. doi: 10.1007/s00520-001-0329-9 PMID: 11904789Maimon, Y.; Samuels, N.; Cohen, Z.; Berger, R.; Rosenthal, D.S. Botanical formula LCS101: A multi-targeted approach to cancer care. Integr. Cancer Ther., 2018, 17(4), 1020-1026. doi: 10.1177/1534735418801528 PMID: 30303021Cohen, Z.; Maimon, Y.; Yoeli-Lerner, M.; Yang, P.; Samuels, N.; Berger, R. Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: Implications for cancer treatment. Int. J. Oncol., 2015, 46(1), 308-316. doi: 10.3892/ijo.2014.2711 PMID: 25333773Maimon, Y.; Karaush, V.; Yaal-Hahoshen, N.; Ben-Yosef, R.; Ron, I.; Vexler, A.; Lev-Ari, S. Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines. J. Int. Med. Res., 2010, 38(6), 2033-2039. doi: 10.1177/147323001003800617 PMID: 21227007Yaal-Hahoshen, N.; Maimon, Y.; Siegelmann-Danieli, N.; Lev-Ari, S.; Ron, I.G.; Sperber, F.; Samuels, N.; Shoham, J.; Merimsky, O. A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer. Oncologist, 2011, 16(9), 1197-1202. doi: 10.1634/theoncologist.2011-0150 PMID: 21712486Kawai, H.; Saito, Y. Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non‑small cell lung cancer. Mol. Clin. Oncol., 2020, 13(3), 13. doi: 10.3892/mco.2020.2083 PMID: 32754327Testart-Paillet, D.; Girard, P.; You, B.; Freyer, G.; Pobel, C.; Tranchand, B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit. Rev. Oncol. Hematol., 2007, 63(1), 1-11. doi: 10.1016/j.critrevonc.2007.01.005 PMID: 17418588Kambhampati, S.P.; Mishra, M.K.; Mastorakos, P.; Oh, Y.; Lutty, G.A.; Kannan, R.M. Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells. Eur. J. Pharm. Biopharm., 2015, 95(Pt B), 239-249. doi: 10.1016/j.ejpb.2015.02.013 PMID: 25701805Teschke, R.; Wolff, A.; Frenzel, C.; Eickhoff, A.; Schulze, J. Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. World J. Gastroenterol., 2015, 21(15), 4466-4490. doi: 10.3748/wjg.v21.i15.4466 PMID: 25914456Li, H; Ma, Q; Al, P; Zhang, HM; Li, M Treatment of chemotherapy-induced leucopenia in patients with malignant tumor by Chinese herbal medicine: A systematic review and meta-analysis of randomized clinical trials. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2015, 35(2), 157-66.Kohguchi, M.; Kunikata, T.; Watanabe, H.; Kudo, N.; Shibuya, T.; Ishihara, T.; Iwaki, K.; Ikeda, M.; Fukuda, S.; Kurimoto, M. Immuno-potentiating effects of the antler-shaped fruiting body of Ganoderma lucidum (Rokkaku-Reishi). Biosci. Biotechnol. Biochem., 2004, 68(4), 881-887. doi: 10.1271/bbb.68.881 PMID: 15118318Nonaka, Y.; Ishibashi, H.; Nakai, M.; Shibata, H.; Kiso, Y.; Abe, S. Soothing effect of Ganoderma lucidum antlered form on cyclophosphamide-induced adverse reaction. Gan To Kagaku Ryoho, 2005, 32(11), 1586-1588. PMID: 16315878Zee-Cheng, R.K. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find. Exp. Clin. Pharmacol., 1992, 14(9), 725-736. PMID: 1294861Vayalil, P.K.; Kuttan, G.; Kuttan, R. Rasayanas: Evidence for the concept of prevention of diseases. Am. J. Chin. Med., 2002, 30(1), 155-171. doi: 10.1142/S0192415X02000168 PMID: 12067090Vayalil, P.K.; Kuttan, G.; Kuttan, R. Protective effects of Rasayanas on cyclophosphamide- and radiation-induced damage. J. Altern. Complement. Med., 2002, 8(6), 787-796. doi: 10.1089/10755530260511801 PMID: 12614532Menon, L.G.; Kuttan, R.; Kuttan, G. Effect of rasayanas in the inhibition of lung metastasis induced by B16F-10 melanoma cells. J. Exp. Clin. Cancer Res., 1997, 16(4), 365-368. PMID: 9505206Diasio, R.B.; Harris, B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 1989, 16(4), 215-237. doi: 10.2165/00003088-198916040-00002 PMID: 2656050Anand, A.J. Fluorouracil Cardiotoxicity. Ann. Pharmacother., 1994, 28(3), 374-378. doi: 10.1177/106002809402800314 PMID: 8193429Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer, 2003, 3(5), 330-338. doi: 10.1038/nrc1074 PMID: 12724731Sun, X.X.; Dai, M.S.; Lu, H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem., 2007, 282(11), 8052-8059. doi: 10.1074/jbc.M610621200 PMID: 17242401Wigmore, P.M.; Mustafa, S.; El-Beltagy, M.; Lyons, L.; Umka, J.; Bennett, G. Effects of 5-FU. Adv Exp Med Biol., 2010, 678, 157-164. doi: 10.1007/978-1-4419-6306-2_20Steger, F.; Hautmann, M.G.; Kölbl, O. 5-FU-induced cardiac toxicity - an underestimated problem in radiooncology? Radiat. Oncol., 2012, 7(1), 212. doi: 10.1186/1748-717X-7-212 PMID: 23241239Zhang, D.; Ma, J. Mitochondrial dynamics in rat heart induced by 5-fluorouracil. Med. Sci. Monit., 2018, 24, 6666-6672. doi: 10.12659/MSM.910537 PMID: 30240386Shiga, T.; Hiraide, M. Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Curr. Treat. Options Oncol., 2020, 21(4), 27. doi: 10.1007/s11864-020-0719-1 PMID: 32266582Dasgeb, B.; Kornreich, D.; McGuinn, K.; Okon, L.; Brownell, I.; Sackett, D.L. Colchicine: An ancient drug with novel applications. Br. J. Dermatol., 2018, 178(2), 350-356. doi: 10.1111/bjd.15896 PMID: 28832953Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S.; Kaldas, M.; Gogia, M.; Perez-Ruiz, F.; Taylor, W.; Lioté, F.; Choi, H.; Singh, J.A.; Dalbeth, N.; Kaplan, S.; Niyyar, V.; Jones, D.; Yarows, S.A.; Roessler, B.; Kerr, G.; King, C.; Levy, G.; Furst, D.E.; Edwards, N.L.; Mandell, B.; Schumacher, H.R.; Robbins, M.; Wenger, N.; Terkeltaub, R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken), 2012, 64(10), 1431-1446. doi: 10.1002/acr.21772 PMID: 23024028Caviston, J.P.; Holzbaur, E.L.F. Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol., 2006, 16(10), 530-537. doi: 10.1016/j.tcb.2006.08.002 PMID: 16938456Bakhta, O.; Blanchard, S.; Guihot, A.L.; Tamareille, S.; Mirebeau-Prunier, D.; Jeannin, P.; Prunier, F. Cardioprotective role of colchicine against inflammatory injury in a rat model of acute myocardial infarction. J. Cardiovasc. Pharmacol. Ther., 2018, 23(5), 446-455. doi: 10.1177/1074248418763611 PMID: 29658326Forrat, R.; Sebbag, L.; Ferrera, R.; Hadour, G.; Canet, E.; Tabib, A.; de Lorgeril, M. Effect of colchicine on circulating and myocardial neutrophils and on infarct size in a canine model of ischemia and reperfusion. J. Cardiovasc. Pharmacol., 1996, 27(6), 876-883. doi: 10.1097/00005344-199606000-00016 PMID: 8761856Couzin-Frankel, J. Anti-inflammatory prevents heart attacks; American Association for the Advancement of Science, 2017. doi: 10.1126/science.357.6354.855Safarpour, S; Safarpour, S; Pirzadeh, M; Moghadamnia, AA; Ebrahimpour, A; Shirafkan, F Colchicine ameliorates 5-fluorouracil-induced cardiotoxicity in rats. Oxid Med Cell Longev, 2022, 2022, 6194532.Miltenburg, N.C.; Boogerd, W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat. Rev., 2014, 40(7), 872-882. doi: 10.1016/j.ctrv.2014.04.004 PMID: 24830939Jaggi, A.S.; Singh, N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology, 2012, 291(1-3), 1-9. doi: 10.1016/j.tox.2011.10.019 PMID: 22079234Egan, M.; Burke, E.; Meskell, P.; MacNeela, P.; Dowling, M. Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. J. Res. Nurs., 2015, 20(5), 385-398. doi: 10.1177/1744987115574296Wolf, S.; Barton, D.; Kottschade, L.; Grothey, A.; Loprinzi, C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur. J. Cancer, 2008, 44(11), 1507-1515. doi: 10.1016/j.ejca.2008.04.018 PMID: 18571399Beijers, A.J.M.; Vreugdenhil, G.; Oerlemans, S.; Eurelings, M.; Minnema, M.C.; Eeltink, C.M.; van de Poll-Franse, L.V.; Mols, F. Chemotherapy-induced neuropathy in multiple myeloma: Influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support. Care Cancer, 2016, 24(6), 2411-2420. doi: 10.1007/s00520-015-3032-y PMID: 26634561Smith, J.A.; Benbow, S.J. , 2015.Hausheer, F.H.; Schilsky, R.L.; Bain, S.; Berghorn, E.J.; Lieberman, F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.Seminars in oncology; Elsevier, 2006, pp. 15-49. doi: 10.1053/j.seminoncol.2005.12.010Grothey, A. Clinical management of oxaliplatin-associated neurotoxicity. Clin. Colorectal Cancer, 2005, 5(Suppl. 1), S38-S46. doi: 10.3816/CCC.2005.s.006 PMID: 15871765Kushlaf, H.A. Emerging toxic neuropathies and myopathies. Neurol. Clin., 2011, 29(3), 679-687. doi: 10.1016/j.ncl.2011.05.009 PMID: 21803218Kuncl, R.W.; George, E.B. Toxic neuropathies and myopathies. Curr. Opin. Neurol., 1993, 6(5), 695-704. doi: 10.1097/00019052-199310000-00004 PMID: 8293140Flatters, S.J.L.; Xiao, W.H.; Bennett, G.J. Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci. Lett., 2006, 397(3), 219-223. doi: 10.1016/j.neulet.2005.12.013 PMID: 16406309Cavaletti, G. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity? Oncologist, 2011, 16(12), 1667-1668. doi: 10.1634/theoncologist.2011-0343 PMID: 22128117Ta, L.E.; Schmelzer, J.D.; Bieber, A.J.; Loprinzi, C.L.; Sieck, G.C.; Brederson, J.D.; Low, P.A.; Windebank, A.J. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One, 2013, 8(1), e54161. doi: 10.1371/journal.pone.0054161 PMID: 23326593Wolf, R.C.; Sambataro, F.; Vasic, N.; Schönfeldt-Lecuona, C.; Ecker, D.; Landwehrmeyer, B. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington’s disease. Exp. Neurol., 2008, 213(1), 137-144. doi: 10.1016/j.expneurol.2008.05.017 PMID: 18588876Ceresa, C.; Cavaletti, G. Drug transporters in chemotherapy induced peripheral neurotoxicity: Current knowledge and clinical implications. Curr. Med. Chem., 2011, 18(3), 329-341. doi: 10.2174/092986711794839160 PMID: 21143122Jordan, M. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents, 2012, 2(1), 1-17. doi: 10.2174/1568011023354290 PMID: 12678749Verstappen, C.C.P.; Koeppen, S.; Heimans, J.J.; Huijgens, P.C.; Scheulen, M.E.; Strumberg, D.; Kiburg, B.; Postma, T.J. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology, 2005, 64(6), 1076-1077. doi: 10.1212/01.WNL.0000154642.45474.28 PMID: 15781834Sharma, V.; Singh, I.; Chaudhary, P. Acorus calamus (The Healing Plant): A review on its medicinal potential, micropropagation and conservation. Nat. Prod. Res., 2014, 28(18), 1454-1466. doi: 10.1080/14786419.2014.915827 PMID: 24824923Shah, P.; Deshmukh, P.B.; Joshi, S.V.; Ghag, M.; Kulkarni, Y.; Vyas, B.; Shah, D.R. Toxicity study of ethanolic extract of Acorus calamus rhizome. Int. J. Green Pharm., 2012, 6(1), 29. doi: 10.4103/0973-8258.97119Akram, M.; Akhtar, N.; Asif, H.M.; Shah, P.A.; Saeed, T.; Mahmood, A. Butea monosperma Lam.: A review. J. Med. Plants Res., 2011, 5, 3994-3996.Madhavi, A. An overview of Butea monosperma (Flame of Forest). World J. Pharm. Pharm. Sci., 2013, 3, 307-319.Rahn, E.J.; Makriyannis, A.; Hohmann, A.G. Activation of cannabinoid CB 1 and CB 2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br. J. Pharmacol., 2007, 152(5), 765-777. doi: 10.1038/sj.bjp.0707333 PMID: 17572696Nagarkatti, P.; Pandey, R.; Rieder, S.A.; Hegde, V.L.; Nagarkatti, M. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem., 2009, 1(7), 1333-1349. doi: 10.4155/fmc.09.93 PMID: 20191092Rahn, E.J.; Hohmann, A.G. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics, 2009, 6(4), 713-737. doi: 10.1016/j.nurt.2009.08.002 PMID: 19789075Isah, T. Rethinking Ginkgo biloba L.: Medicinal uses and conservation. Pharmacogn. Rev., 2015, 9(18), 140-148. doi: 10.4103/0973-7847.162137 PMID: 26392712Pattanayak, P.; Behera, P.; Das, D.; Panda, S. Ocimum sanctum Linn. A reservoir plant for therapeutic applications: An overview. Pharmacogn. Rev., 2010, 4(7), 95-105. doi: 10.4103/0973-7847.65323 PMID: 22228948Kelm, M.A.; Nair, M.G.; Strasburg, G.M.; DeWitt, D.L. Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine, 2000, 7(1), 7-13. doi: 10.1016/S0944-7113(00)80015-X PMID: 10782484Ramappa, V.; Aithal, G.P. Hepatotoxicity related to anti-tuberculosis drugs: Mechanisms and management. J. Clin. Exp. Hepatol., 2013, 3(1), 37-49. doi: 10.1016/j.jceh.2012.12.001 PMID: 25755470Oun, R.; Moussa, Y.E.; Wheate, N.J. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans., 2018, 47(19), 6645-6653. doi: 10.1039/C8DT00838H PMID: 29632935Quintanilha, J.C.F.; de Sousa, V.M.; Visacri, M.B.; Amaral, L.S.; Santos, R.M.M.; Zambrano, T.; Salazar, L.A.; Moriel, P. Involvement of cytochrome P450 in cisplatin treatment: Implications for toxicity. Cancer Chemother. Pharmacol., 2017, 80(2), 223-233. doi: 10.1007/s00280-017-3358-x PMID: 28612092Lu, Y.; Cederbaum, A.I. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol. Sci., 2006, 89(2), 515-523. doi: 10.1093/toxsci/kfj031 PMID: 16251482Kamble, P.R.; Bhiwgade, D.A. Cisplatin induced histological and ultrastructural alterations in liver tissue of rat. J. Cytol. Histol., 2011, 2(6), 128. doi: 10.4172/2157-7099.1000128Lu, Y.; Cederbaum, A.I. Cytochrome P450s and alcoholic liver disease. Curr. Pharm. Des., 2018, 24(14), 1502-1517. doi: 10.2174/1381612824666180410091511 PMID: 29637855Pratibha, R.; Sameer, R.; Rataboli, P.V.; Bhiwgade, D.A.; Dhume, C.Y. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Eur. J. Pharmacol., 2006, 532(3), 290-293. doi: 10.1016/j.ejphar.2006.01.007 PMID: 16458885Singh, N.; Magotra, R.; Sharma, A.K.; Ahmed, M.; Khajuria, V. Effect of cisplatin on liver of male albino rats. J. Evol. Med. Dent. Sci., 2015, 4(52), 8993-8998. doi: 10.14260/jemds/2015/1305Abd Rashid, N.; Abd Halim, S.A.S.; Teoh, S.L.; Budin, S.B.; Hussan, F.; Adib Ridzuan, N.R.; Abdul Jalil, N.A. The role of natural antioxidants in cisplatin-induced hepatotoxicity. Biomed. Pharmacother., 2021, 144, 112328. doi: 10.1016/j.biopha.2021.112328 PMID: 34653753Aeri, V.; Ilyas, U.; Katare, D.P.; Naseef, P. A review on hepatoprotective and immunomodulatory herbal plants. Pharmacogn. Rev., 2016, 10(19), 66-70. doi: 10.4103/0973-7847.176544 PMID: 27041876Kim, Y.S.; Hwang, J.W.; Sung, S.H.; Jeon, Y.J.; Jeong, J.H.; Jeon, B.T.; Moon, S.H.; Park, P.J. Antioxidant activity and protective effect of extract of Celosia cristata L. flower on tert-butyl hydroperoxide-induced oxidative hepatotoxicity. Food Chem., 2015, 168, 572-579. doi: 10.1016/j.foodchem.2014.07.106 PMID: 25172750Sharifi-Rigi, A.; Heidarian, E.; Amini, S.A. Protective and anti-inflammatory effects of hydroalcoholic leaf extract of Origanum vulgare on oxidative stress, TNF-α gene expression and liver histological changes in paraquat-induced hepatotoxicity in rats. Arch. Physiol. Biochem., 2019, 125(1), 56-63. doi: 10.1080/13813455.2018.1437186 PMID: 29425067Zhao, L.; Zhang, N.; Yang, D.; Yang, M.; Guo, X.; He, J.; Wu, W.; Ji, B.; Cheng, Q.; Zhou, F. Protective effects of five structurally diverse flavonoid subgroups against chronic alcohol-induced hepatic damage in a mouse model. Nutrients, 2018, 10(11), 1754. doi: 10.3390/nu10111754 PMID: 30441755Hosseinzadeh, A.; Bahrampour Juybari, K.; Fatemi, M.J.; Kamarul, T.; Tekiyehmaroof, N. Protective effect of ginger (Zingiber officinale roscoe) extract against oxidative stress and mitochondrial apoptosis induced by interleukin-1β in cultured chondrocytes. Cells Tissues Organs, 2017, 204(5-6), 241-50.Michael, O.E.; Titilayo, O.B.; Mohammed, A.U. Protective effect of ethanolic extract of Cucurbita maxima (PUMPKIN) leaf on acetaminophen-induced acute liver toxicity. J. Pharmacogn. Phytother., 2018, 10(8), 142-148. doi: 10.5897/JPP2018.0498Metri, K.; Bhargav, H.; Chowdhury, P.; Koka, P.S. Ayurveda for chemo-radiotherapy induced side effects in cancer patients. J. Stem Cells, 2013, 8(2), 115-129. PMID: 24698988Frassová, Z.; Rudá-Kučerová, J. Milk Thistle (Silybum Marianum) as a supportive phytotherapeutic agent in oncology. Klin. Onkol., 2017, 30(6), 426-432. doi: 10.14735/amko2017426 PMID: 29271213Ito, T.; Urushima, H.; Sakaue, M.; Yukawa, S.; Honda, H.; Hirai, K.; Igura, T.; Hayashi, N.; Maeda, K.; Kitagawa, T.; Kondo, K. Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy-the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy. Nutr. Cancer, 2014, 66(3), 377-382. doi: 10.1080/01635581.2014.884232 PMID: 24611562Man, Q.; Deng, Y.; Li, P.; Ma, J.; Yang, Z.; Yang, X.; Zhou, Y.; Yan, X. Licorice ameliorates cisplatin-induced hepatotoxicity through antiapoptosis, antioxidative stress, anti-inflammation, and acceleration of metabolism. Front. Pharmacol., 2020, 11, 563750. doi: 10.3389/fphar.2020.563750 PMID: 33240085Awika, J.M.; Rooney, L.W. Sorghum phytochemicals and their potential impact on human health. Phytochemistry, 2004, 65(9), 1199-1221. doi: 10.1016/j.phytochem.2004.04.001 PMID: 15184005Rohdewald, P. A review of the French maritime pine bark extract (Pycnogenol®), a herbal medication with a diverse clinical pharmacology. Int. J. Clin. Pharmacol. Ther., 2002, 40(4), 158-168. doi: 10.5414/CPP40158 PMID: 11996210González-Juárez, D.E.; Escobedo-Moratilla, A.; Flores, J.; Hidalgo-Figueroa, S.; Martínez-Tagüeña, N.; Morales-Jiménez, J.; Muñiz-Ramírez, A.; Pastor-Palacios, G.; Pérez-Miranda, S.; Ramírez-Hernández, A.; Trujillo, J.; Bautista, E. A review of the Ephedra genus: Distribution, ecology, ethnobotany, phytochemistry and pharmacological properties. Molecules, 2020, 25(14), 3283. doi: 10.3390/molecules25143283 PMID: 32698308Hyuga, S.; Hyuga, M.; Oshima, N.; Maruyama, T.; Kamakura, H.; Yamashita, T.; Yoshimura, M.; Amakura, Y.; Hakamatsuka, T.; Odaguchi, H.; Goda, Y.; Hanawa, T. Ephedrine alkaloids-free Ephedra Herb extract: A safer alternative to ephedra with comparable analgesic, anticancer, and anti-influenza activities. J. Nat. Med., 2016, 70(3), 571-583. doi: 10.1007/s11418-016-0979-z PMID: 26943796Priyadarsini, K.I.; Maity, D.K.; Naik, G.H.; Kumar, M.S.; Unnikrishnan, M.K.; Satav, J.G.; Mohan, H. Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic. Biol. Med., 2003, 35(5), 475-484. doi: 10.1016/S0891-5849(03)00325-3 PMID: 12927597Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell. Mol. Life Sci., 2008, 65(11), 1631-1652. doi: 10.1007/s00018-008-7452-4 PMID: 18324353Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel), 2010, 2(11), 2490-2518. doi: 10.3390/toxins2112490 PMID: 22069563Perazella, M.A.; Moeckel, G.W. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Seminars in nephrology; Elsevier, 2010, pp. 570-581. doi: 10.1016/j.semnephrol.2010.09.005Lameire, N. Nephrotoxicity of recent anti-cancer agents. Clin. Kidney J., 2014, 7(1), 11-22. doi: 10.1093/ckj/sft135 PMID: 25859345Sadeghi, F.; Nematbakhsh, M.; Noori-Diziche, A.; Eshraghi-Jazi, F.; Talebi, A.; Nasri, H.; Mansouri, A.; Dehghani, A.; Saberi, S.; Shirdavani, S.; Ashrafi, F. Protective effect of pomegranate flower extract against gentamicin-induced renal toxicity in male rats. J. Renal Inj. Prev., 2015, 4(2), 45-50. PMID: 26060837Pourjabali, M.; Mohammadrezaei-Khorramabadi, R.; Abbaszadeh, S.; Naghdi, N.; Naji-Haddadi, S.; Bahmani, F. Medicinal plants used for hypertension. J Pharm Sci Res., 2017, 9(5), 537.Jivad, N.; Bahmani, M.; Asadi-Samani, M. A review of the most important medicinal plants effective on wound healing on ethnobotany evidence of Iran. Pharm. Lett., 2016, 8(2), 353-357.Kooti, W.; Hasanzadeh-Noohi, Z.; Sharafi-Ahvazi, N.; Asadi-Samani, M.; Ashtary-Larky, D. Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa). Chin. J. Nat. Med., 2016, 14(10), 732-745. doi: 10.1016/S1875-5364(16)30088-7 PMID: 28236403Sani, M.R.M.; Asadi-Samani, M.; Rouhi-Boroujeni, H.; Banitalebi-Dehkordi, M. Phytopharmacology and phytotherapy of regulatory T cells: A new approach to treat multiple sclerosis. Pharm. Lett., 2016, 8(3), 215-220.Rouhi-Boroujeni, H.; Asadi-Samani, M.; Moradi, M.T. A review of the medicinal plants effective on headache based on the ethnobotanical documents of Iran. Pharm. Lett., 2016, 8(3), 37-42.Parsaei, P.; Bahmani, M.; Karimi, M.; Naghdi, N.; Asadi-Samani, M.; Rafieian-Kopaei, M. A review of analgesic medicinal plants in Iran. Pharm. Lett., 2016, 8(2), 43-51.Parsaei, P.; Bahmani, M.; Naghdi, N.; Asadi-Samani, M.; Rafieian-Kopaei, M. The most important medicinal plants effective on constipation by the ethnobotanical documents in Iran: A review. Pharm. Lett., 2016, 8(2), 188-194.Çayır, K.; Karadeniz, A.; Şimşek, N.; Yıldırım, S.; Karakuş, E.; Kara, A.; Akkoyun, H.T.; Şengül, E. Pomegranate seed extract attenuates chemotherapy-induced acute nephrotoxicity and hepatotoxicity in rats. J. Med. Food, 2011, 14(10), 1254-1262. doi: 10.1089/jmf.2010.0286 PMID: 21548807Boroushaki, M.T.; Rajabian, A.; Farzadnia, M.; Hoseini, A.; Poorlashkari, M.; Taghavi, A.; Dolati, K.; Bazmandegan, G. Protective effect of pomegranate seed oil against cisplatin-induced nephrotoxicity in rat. Ren. Fail., 2015, 37(8), 1338-1343. doi: 10.3109/0886022X.2015.1073496 PMID: 26288026Karwasra, R.; Kalra, P.; Gupta, Y.K.; Saini, D.; Kumar, A.; Singh, S. Antioxidant and anti-inflammatory potential of pomegranate rind extract to ameliorate cisplatin-induced acute kidney injury. Food Funct., 2016, 7(7), 3091-3101. doi: 10.1039/C6FO00188B PMID: 27273121Khan, S.A.; Priyamvada, S.; Khan, W.; Khan, S.; Farooq, N.; Yusufi, A.N.K. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol. Res., 2009, 60(5), 382-391. doi: 10.1016/j.phrs.2009.07.007 PMID: 19647078Ko, J-L.; Tsai, C-H.; Liu, T-C.; Lin, M-Y.; Lin, H-L.; Ou, C-C. Differential effects of grape juice on gastric emptying and renal function from cisplatin-induced acute adverse toxicity. Hum. Exp. Toxicol., 2016, 35(8), 808-817. doi: 10.1177/0960327115607079 PMID: 26429932Mazumder, P.B.; Devi, H.P. Methanolic Extract of Curcuma caesia Roxb. prevents the toxicity caused by Cyclophosphamide to bone marrow cells, liver and kidney of mice. Pharmacognosy Res., 2016, 8(1), 43-49. doi: 10.4103/0974-8490.171106 PMID: 26941535Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30. doi: 10.3322/caac.21442 PMID: 29313949Pfeiffer, P.; Köhne, C.H.; Qvortrup, C. The changing face of treatment for metastatic colorectal cancer. Expert Rev. Anticancer Ther., 2019, 19(1), 61-70. doi: 10.1080/14737140.2019.1543593 PMID: 30381969Schmoll, H.J.; Van Cutsem, E.; Stein, A.; Valentini, V.; Glimelius, B.; Haustermans, K.; Nordlinger, B.; van de Velde, C.J.; Balmana, J.; Regula, J.; Nagtegaal, I.D.; Beets-Tan, R.G.; Arnold, D.; Ciardiello, F.; Hoff, P.; Kerr, D.; Köhne, C.H.; Labianca, R.; Price, T.; Scheithauer, W.; Sobrero, A.; Tabernero, J.; Aderka, D.; Barroso, S.; Bodoky, G.; Douillard, J.Y.; El Ghazaly, H.; Gallardo, J.; Garin, A.; Glynne-Jones, R.; Jordan, K.; Meshcheryakov, A.; Papamichail, D.; Pfeiffer, P.; Souglakos, I.; Turhal, S.; Cervantes, A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol., 2012, 23(10), 2479-2516. doi: 10.1093/annonc/mds236 PMID: 23012255Lalla, R.V.; Bowen, J.; Barasch, A.; Elting, L.; Epstein, J.; Keefe, D.M.; McGuire, D.B.; Migliorati, C.; Nicolatou-Galitis, O.; Peterson, D.E.; Raber-Durlacher, J.E.; Sonis, S.T.; Elad, S. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, 120(10), 1453-1461. doi: 10.1002/cncr.28592 PMID: 24615748Boussios, S.; Pentheroudakis, G.; Katsanos, K.; Pavlidis, N. Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management. Ann. Gastroenterol., 2012, 25(2), 106-118. PMID: 24713845Andreyev, H.J.N.; Lalji, A.; Mohammed, K.; Muls, A.C.G.; Watkins, D.; Rao, S.; Starling, N.; Chau, I.; Cruse, S.; Pitkaaho, V.; Matthews, J.; Caley, L.; Pittordou, V.; Adams, C.; Wedlake, L. The FOCCUS study: A prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. Support. Care Cancer, 2021, 29(3), 1443-1453. doi: 10.1007/s00520-020-05610-x PMID: 32676853Liu, W.; Ge, T.; Pan, Z.; Leng, Y.; Lv, J.; Li, B. The effects of herbal medicine on epilepsy. Oncotarget, 2017, 8(29), 48385-48397. doi: 10.18632/oncotarget.16801 PMID: 28423368Zhong, L.L.D.; Chen, H.Y.; Cho, W.C.S.; Meng, X.; Tong, Y. The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A systematic review and meta-analysis. Complement. Ther. Med., 2012, 20(4), 240-252. doi: 10.1016/j.ctim.2012.02.004 PMID: 22579437McCulloch, M.; Ly, H.; Broffman, M.; See, C.; Clemons, J.; Chang, R. Chinese herbal medicine and fluorouracil-based chemotherapy for colorectal cancer: A quality-adjusted meta-analysis of randomized controlled trials. Integr. Cancer Ther., 2016, 15(3), 285-307. doi: 10.1177/1534735416638738 PMID: 27151587Lin, S.; An, X.; Guo, Y.; Gu, J.; Xie, T.; Wu, Q.; Sui, X. Meta-analysis of astragalus-containing traditional Chinese medicine combined with chemotherapy for colorectal cancer: Efficacy and safety to tumor response. Front. Oncol., 2019, 9, 749. doi: 10.3389/fonc.2019.00749 PMID: 31456940Liu, S.; Zhang, K.; Hu, X. Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis. Front. Pharmacol., 2022, 13, 1004259. doi: 10.3389/fphar.2022.1004259 PMID: 36523501Motoo, Y.; Seki, T.; Tsutani, K. Traditional Japanese medicine, Kampo: Its history and current status. Chin. J. Integr. Med., 2011, 17(2), 85-87. doi: 10.1007/s11655-011-0653-y PMID: 21390572Hesketh, P.J. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 2008, 358(23), 2482-2494. doi: 10.1056/NEJMra0706547 PMID: 18525044Roila, F.; Herrstedt, J.; Aapro, M.; Gralla, R.J.; Einhorn, L.H.; Ballatori, E.; Bria, E.; Clark-Snow, R.A.; Espersen, B.T.; Feyer, P.; Grunberg, S.M.; Hesketh, P.J.; Jordan, K.; Kris, M.G.; Maranzano, E.; Molassiotis, A.; Morrow, G.; Olver, I.; Rapoport, B.L.; Rittenberg, C.; Saito, M.; Tonato, M.; Warr, D. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann. Oncol., 2010, 21(Suppl. 5), v232-v243. doi: 10.1093/annonc/mdq194 PMID: 20555089De Vry, J.; Schreiber, R. Effects of selected serotonin 5-HT 1 and 5-HT 2 receptor agonists on feeding behavior: Possible mechanisms of action. Neurosci. Biobehav. Rev., 2000, 24(3), 341-353. doi: 10.1016/S0149-7634(99)00083-4 PMID: 10781694Tatsuta, M.; Iishi, H. Effect of treatment with Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment. Pharmacol. Ther., 1993, 7(4), 459-462. doi: 10.1111/j.1365-2036.1993.tb00120.x PMID: 8218760Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 1979, 95(2), 351-358. doi: 10.1016/0003-2697(79)90738-3 PMID: 36810Takeda, H.; Sadakane, C.; Hattori, T.; Katsurada, T.; Ohkawara, T.; Nagai, K.; Asaka, M. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology, 2008, 134(7), 2004-2013. doi: 10.1053/j.gastro.2008.02.078 PMID: 18439428Yakabi, K.; Kurosawa, S.; Tamai, M.; Yuzurihara, M.; Nahata, M.; Ohno, S.; Ro, S.; Kato, S.; Aoyama, T.; Sakurada, T.; Takabayashi, H.; Hattori, T. Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. Regul. Pept., 2010, 161(1-3), 97-105. doi: 10.1016/j.regpep.2010.02.003 PMID: 20171995Kase, Y.; Hayakawa, T.; Aburada, M.; Komatsu, Y.; Kamataki, T. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn. J. Pharmacol., 1997, 75(4), 407-413. doi: 10.1254/jjp.75.407 PMID: 9469647Narita, M.; Nagai, E.; Hagiwara, H.; Aburada, M.; Yokoi, T.; Kamataki, T. Inhibition of β-glucuronidase by natural glucuronides of Kampo, medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 1993, 23(1), 5-10. doi: 10.3109/00498259309059356 PMID: 8484262Takasuna, K.; Kasai, Y.; Kitano, Y.; Mori, K.; Kobayashi, R.; Hagiwara, T.; Kakihata, K.; Hirohashi, M.; Nomura, M.; Nagai, E.; Kamataki, T. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res., 1995, 86(10), 978-984. doi: 10.1111/j.1349-7006.1995.tb03010.x PMID: 7493918Perazella, M.A. Drug use and nephrotoxicity in the intensive care unit. Kidney Int., 2012, 81(12), 1172-1178. doi: 10.1038/ki.2010.475 PMID: 21124300